Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02826512
Recruitment Status : Suspended (Not enough eligble patient can be found, too many screen failures)
First Posted : July 11, 2016
Last Update Posted : March 22, 2022
Tesaro, Inc.
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:
Patients with locally recurrent BRCA1-like, HER2-negative breast cancer that cannot be treated with curative intent by local treatment (surgery, radiotherapy +/- hyperthermia) or patients with metastatic BRCA1-like, HER2-negative breast cancer that have received a maximum of one prior line of treatment for incurable disease will be treated with Niraparib until disease progression

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Niraparib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
Actual Study Start Date : May 15, 2018
Estimated Primary Completion Date : July 1, 2022
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Niraparib
niraparib 300 mg QD continuously
Drug: Niraparib
niraparib 300 mg QD continuously

Primary Outcome Measures :
  1. Progression free survival [ Time Frame: From date of randomization until date of first documented progression or date of death, whichever comes first, assessed up to 120 months ]

Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: Assessed up to 120 months ]
  2. Duration of response [ Time Frame: Assessed up to 120 months ]
    Time from date of response to progression of disease

  3. Toxicity; Incidence of toxicity, graded according to National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.03 [ Time Frame: up to 30 days after end of treatment ]
    Adverse events will be graded according to NCI Common Toxicity Criteria version 4.03

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological proof of advanced, HER2 negative breast cancer;
  • Fresh frozen primary tumor sample available or metastasis accessible for fresh frozen biopsy;
  • The tumor must be BRCA1-like, as identified by Agendia's RNA-based BRCAness classifier;
  • Only the following patients may be referred for BRCA1-like testing: all patients that had triple negative primary breast cancer; hormone-receptor positive, HER2-negative primary breast cancer patients with a histological grade III breast cancer; Breast cancer patients carrying a BRCA1 and/or BRCA2 germ line mutation.
  • Pretreatment containing an anthracycline and/or taxane in the (neo-)adjuvant or metastatic setting received, or if not, then discussed with the patient whether it is justified to forego these treatments;
  • Maximum of one prior line of chemotherapy for advanced disease.
  • Age ≥ 18 years;
  • Able and willing to give written informed consent;
  • WHO performance status of 0, 1 or 2;
  • Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and antitumor activity;
  • Measurable or evaluable disease according to RECIST 1.1 criteria;
  • Minimal acceptable safety laboratory values

    • ANC of ≥ 1.5 x 109 /L
    • Platelet count of ≥ 150 x 109 /L
    • Hemoglobin ≥ 10 g/dL (6.21mmol/L)
    • Hepatic function as defined by total serum bilirubin ≤ 1. 5 x ULN (except elevated bilirubin due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin), ASAT and ALAT < 2.5 x ULN or <5 x ULN in case of liver metastasis
  • Renal function as defined by serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula);
  • Negative pregnancy test (urine/serum) for female patients with childbearing potential.

Exclusion Criteria:

  • Any treatment with investigational drugs within 28 days prior to receiving the first dose of investigational treatment; or within 21 days for standard chemotherapy; or within 14 days for weekly scheduled chemotherapeutic regimens or endocrine therapy;
  • Patients who have progressed on previous palliative treatment with PARP1-inhibitors, platinum compounds or high dose alkylating agents with autologous stem cell rescue, since preclinical and anecdotal clinical data in breast cancer indicate that these cancers have acquired resistance to PARP-inhibitors based on genetic reversion, epigenetic modifications, or as yet unknown mechanisms. Platinum-sensitive or PARP1-inhibitor-sensitive patients who stopped for reasons other than progression are eligible;
  • Patients who received high-dose alkylating agents with autologous stem cell rescue in the (neo)adjuvant setting, unless these treatments had been received longer than 3 years ago;
  • Pretreatment not containing an anthracycline and/or taxane, either in the (neo-) adjuvant or metastatic setting unless these treatments are not indicated;
  • Women who have a positive pregnancy test (urine/serum) and/or who are breast feeding;
  • Unreliable contraceptive methods. Women and men enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: oral, injected or implanted hormonal methods, intra-uterine devices or systems, condom or other barrier contraceptive measures, sterilization and true abstinence);
  • Radiotherapy within the last four weeks prior to receiving the first dose of investigational treatment; except 1x8 Gray for pain palliation then a seven days interval should be maintained;
  • Patients must not have any known history of myelodysplastic syndrome (MDS) or other cytogenetic abnormality associated with MDS
  • Patients must not have known persistent (> 4 weeks) ≥ Grade 2 toxicity from prior cancer therapy (except for alopecia gr 2).
  • Patients must not have known ≥ Grade 3 hematological toxicity with the last chemotherapy regimen
  • Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients;
  • Patients with an active hepatitis B or C;
  • Recent myocardial infarction (< six months) or unstable angina;
  • Symptomatic brain metastases or leptomeningeal metastases. If adequately treated with resection and/or irradiation and patients are at least four weeks completely free of symptoms of these metastases and without medication related to these metastases (steroids are allowed) patients could be eligible if all other in- and exclusion criteria are obeyed;
  • Any medical condition not yet specified above that is considered to possibly, probably or definitely interfere with study procedures, including adequate follow-up and compliance and/or would jeopardize safe treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02826512

Layout table for location information
Antoni van Leeuwenhoek
Amsterdam, Netherlands, 1066 CX
Deventer ziekenhuis
Deventer, Netherlands
Erasmus Medical Center Cancer Institute
Rotterdam, Netherlands, 3015CE
Sponsors and Collaborators
The Netherlands Cancer Institute
Tesaro, Inc.
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute Identifier: NCT02826512    
Other Study ID Numbers: M14ABC
First Posted: July 11, 2016    Key Record Dates
Last Update Posted: March 22, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: to be determined

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute:
HER2 negative
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents